乳腺癌患者血清中hMAM和CD147水平检测及其临床意义

doi:10.13481/j.1671-587x.20180627

摘要/Abstract

摘要： 目的：探讨乳腺癌患者血清中人乳腺珠蛋白（hMAM）和基质金属蛋白酶诱惑因子（CD147）水平及阳性表达率，阐明其在乳腺癌诊断中的临床意义。方法：选择122例乳腺癌患者（乳腺癌组）、21例乳腺纤维腺瘤患者（乳腺纤维腺瘤组）和16名健康对照者（健康对照组）作为研究对象。收集各组研究对象的血清，采用ELISA法检测各组研究对象血清中hMAM和CD147水平及阳性表达率，分析不同临床病理特征患者血清hMAM和CD147水平及阳性表达率。采用受试者工作特征（ROC）曲线确定乳腺癌患者血清中hMAM和CD147的cut-off值，确定其诊断乳腺癌的敏感度和特异度。结果：乳腺癌组患者血清中hMAM和CD147水平均高于健康对照组和乳腺纤维腺瘤组（P<0.05）。乳腺癌组患者血清中hMAM和CD147阳性表达率均高于健康对照组和乳腺纤维腺瘤组（P<0.01）；乳腺癌组患者血清中hMAM联合CD147的阳性表达率高于健康对照组和乳腺纤维腺瘤组（P<0.01）。是否有淋巴结转移乳腺癌患者血清中hMAM和CD147阳性表达率比较差异有统计学意义（χ²=10.375，P<0.01；χ²=15.556，P<0.01）。不同TNM分期、雌激素受体（ER）和人表皮生长因子受体2（Her-2）乳腺癌患者血清中CD147阳性表达率比较差异有统计学意义（χ²=8157，P<0.05；χ²=6.035，P<0.05；χ²=5.385，P<0.05）。随着TNM分期增加，乳腺癌患者血清中hMAM和CD147阳性表达率均呈递增趋势。hMAM的ROC曲线下面积（AUC）为0.809，95% CI：0.703~0.916；CD147的AUC为0.721，95% CI：0.582~0.861。hMAM的cut-off值为6.51 μg·L^-1，诊断乳腺癌的敏感度和特异度分别为61.1%和87.5%；CD147的cut-off值为144.92 ng·L^-1，诊断乳腺癌的敏感度和特异度分别为73.6%和68.7%；二者联合检测时AUC为0.880，95% CI：0.798~0.962，诊断乳腺癌敏感度和特异度分别为80.6%和81.2%。结论：血清中hMAM水平诊断乳腺癌具有较高的敏感度和特异度，hMAM与CD147联合检测可以提高诊断阳性率。

关键词: 乳腺肿瘤, 人乳腺珠蛋白, 基质金属蛋白酶诱惑因子, 敏感度, 特异度

Abstract: Objective: To explore the serum levels and the positive expression rates of human mammaglobin(hMAM) and extracellular matrix metalloproteinase inducer(CD147) of the patients with breast cancer,and to clarify their clinical significnaces in the diagnosis of breast cancer.Methods: A total of 122 patients with breast cancer(breast cancer group), 21 patients with breast fibroadenoma (breast fibroadenoma group)and 16 healthy controls (healthy control group)were selected as the subjects. The serum samples of subjects in various groups were collected.The serum levels and the positive expression rates of hMAM and CD147 of the subjects in various groups were measured by ELISA method. The serum levels and the positive expression rates of hMAM and CD147 of the breast cancer patients with different clinicopathological features were analyzed.The cut-off values of serum levels of hMAM and CD147 of the patients with breast cancer and their sensitivities and specificities in the dignosis of breast cancer were comfirmed by receiver operating characteristic (ROC) curve.Results: The serum levels of hMAM and CD147 of the patients in breast cancer group were higher than those in healthy control group and breast fibroadenoma group(P<0.05). The positive expression rates of hMAM and CD147 of the patients in breast cancer group were higher than those in healthy control group and breast fibroadenoma group(P<0.01); while the positive expression rates of serum hMAM combined with CD147 of the patients in breast cancer group were higher than those in healthy control group and breast fibroadenoma group(P<0.01).There were significant differences in the positive expression rates of serum hMAM and CD147 of breast cancer patients with lymph node metastasis or not (χ²=10.375,P<0.01; χ²=15.556, P<0.01). There were significant differences in the positive expression rates of serum CD147 of the breast cancer patients with different TNM stages, ER and Her-2 (χ²=8157, P<0.05;χ²=6.035,P<0.05; χ²=5.385,P<0.05).With the increasing of TNM stages, the positive expression rates of serum hMAM and CD147 were increased.The area under ROC curve(AUC) of serum level of hMAM was 0.809, 95%CI:0.703-0.916;the AUC of serum level of CD147 was 0.721, 95% CI:0.582-0.861. When the cut-off value of hMAM was 6.51 μg·L^-1,its sensitivity and specificity were 61.1% and 87.5%, respectively. The sensitivity and specificity were 73.6% and 68.7% respectively when the cut-off value of CD147 was 144.92 ng·L^-1. The AUC of detection of hMAM combined with CD147 was 0.880, 95% CI:0.798-0.962; the sensitivity and specificity were 80.6% and 81.2%, respectively.Conclusion: The serum level of hMAM has the high sensitivity and specificity in the diagnosis of breast cancer. Combined detection of hMAM and CD147 can improve the positive rate of diagnosis.

Key words: breast neoplasms, human mammaglobin, extracellular matrix metalloproteinase inducer, sensitivity, specificity

中图分类号:

R737.9

于秀艳, 张晓伟, 丛占杰, 李铤, 吴雪峰. 乳腺癌患者血清中hMAM和CD147水平检测及其临床意义[J]. 吉林大学学报(医学版), 2018, 44(06): 1269-1274.

YU Xiuyan, ZHANG Xiaowei, CONG Zhanjie, LI Ting, WU Xuefeng. Detection of serum hMAM and CD147 levels of patients with breast cancer and its clinical significance[J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1269-1274.

参考文献

[1] Watson MA, Fleming TP. Mammaglobin,a mammary-specific member of the uteroglobin gene family is overexpressed in human breast cancer[J].Cancer Res, 1996, 56(4):860-865.
[2] Becker RM, Darrow C, Zimonjie DB, et al. Identification of mammaglobin B,a novel member of the uteroglobin gene family[J]. Genomics, 1998, 54(1):70-78.
[3] Oloomi M, Moazzezy N, Bouzari S. Modulation of molecular biomarker expression in response to chemotherapy in invasive ductal carcinoma[J]. Biomed Res Int, 2018,2018:7154708.
[4] Li C, Zhang T. Human mammaglobin:A specific marker for breast cancer prognosis[J]. J Buon, 2016, 21(1):35-41.
[5] Lv X, Feng X, Hao X, et al. Anti-hMAM monoclonal antibodies evaluated in breast and non-breast tissues for differential diagnosis implication[J]. Tumori, 2016, 2016(3):264-269.
[6] 武帅,王斌,刘赟.人乳腺珠蛋白在乳腺癌组织中的表达及意义[J].中国药物与临床,2017,17(9):1299-1300.
[7] 刘震,马德寿,沈国双.hMAM在乳腺癌前哨淋巴结中的表达及其临床意义分析[J].现代免疫学,2017,37(5):395-398.
[8] 鲍慧铮,陈力,李思莹,等.CK19联合hMAM检测乳腺癌循环肿瘤细胞的临床价值[J].肿瘤,2014,34(2):153-157.
[9] 于秀艳,张晓伟,野丽莉,等.hMAM联合MMP-9和C-erbB2 mRNA表达检测在乳腺癌外周血微转移诊断中的应用[J].吉林大学学报:医学版,2017,43(5):1009-1014.
[10] Zucker S, Hymowitz M,Rollo EE, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer[J]. Am J Pathol, 2001, 158(6):1921-1928.
[11] 冀峰,吕复君,李延翠.hMAM mRNA表达情况与乳腺癌的关系[J].癌症进展,2018, 16(3):315-317.
[12] 印滇,王亚非,杨莉,等.hMAM水平与乳腺癌早期诊断和癌微转移的相关性及临床意义研究[J].临床和实验医学杂志,2015,14(18):1512-1515.
[13] Al Joudi FS. Human mammaglobin in breast cancer:a brief review of its clinical utility[J]. Indian J Med Res, 2014, 139(5):675-685.
[14] Goedegebuure PS, Watson MA, Viehl CT, et al. Mammaglobin-based strategies for treatment of breast cancer[J]. Curr Cancer Drug Targets, 2004, 4(6):531-542.
[15] Strati A, Markou A, Parisi C, et al. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR[J]. BMC Cancer,2011, 11(1):422.
[16] Zhao S, Yang H, Zhang M, et al. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients[J]. Cell Biochem Biophys, 2013, 65(2):263-273.
[17] Liu Y, Ma L, Liu X, et al. Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer[J]. Exp Ther Med, 2012, 3(3):550-554.
[18] Yang J, Wang R, Li H, et al. Lentivirus mediated RNA interference of EMMPRIN (CD147) gene inhibits the proliferation, matrigel invasion and tumor formation of breast cancer cells[J]. Cancer Biomark, 2016, 17(2):237-247.
[19] 赵超悦,宋润敏,秦晖,等.EMMPRIN糖基化突变质粒的构建及功能检测[J].吉林大学学报:医学版,2014,40(3):583-587.
[20] Dimas DT, Perlepe CD, Sergentanis TN, et al. The prognostic significance of Hsp70/Hsp90 expression in breast cancer:A systematic review and meta-analysis[J]. Anticancer Res, 2018, 38(3):1551-1562.
[21] Luz M, Perez M, Azzalis L, et al. Evaluation of MCT1, MCT4 and CD147 genes in peripheral blood cells of breast cancer patients and their potential use as diagnostic and prognostic markers[J]. Int J Mol Sci, 2017, 18(4):170-180.
[22] 田英,姜专基,张志艳.乳腺癌患者血清hMAM检测的临床意义研究[J].国际检验医学杂志,2013,34(3):302-304.
[23] 杨超,康炜,李建华,等.血清乳腺珠蛋白与乳腺癌的相关性及临床意义探讨[J].检验医学,2014,29(1):61-64.
[24] Xue S, Li SX, Wu ZS, et al. Expression of CD147, matrix metalloproteinases and transforming growth factor beta1 in breast cancer[J]. Chin J Path, 2009, 38(8):524-528.